A pilot study to assess immunogenicity of the prime-boost revaccination strategy using 13-Valent Pneumococcal Conjugate Vaccine followed by 23-Valent Pneumococcal Polysaccharide Vaccine vaccination 8 weeks later in 24 patients with Rheumatoid Arthritis (RA) treated by Methotrexate (MTX) and anti-TNF

Trial Profile

A pilot study to assess immunogenicity of the prime-boost revaccination strategy using 13-Valent Pneumococcal Conjugate Vaccine followed by 23-Valent Pneumococcal Polysaccharide Vaccine vaccination 8 weeks later in 24 patients with Rheumatoid Arthritis (RA) treated by Methotrexate (MTX) and anti-TNF

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine (Primary)
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 12 Dec 2017 New trial record
    • 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top